Además de la miocardiopatía hipertrófica, existen una serie de enfermedades o miocardiopatías que se asocian con hipertrofia ventricular izquierda. Por ello, me gustaría recomendar los siguientes artículos:

  1. Frey N, Luedde M and Katus HA. Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol 2012;9:91-100.
  2. Force T, Bonow RO, Houser SR, et al. Research priorities in hypertrophic cardiomyopathy. Report of a working group of the National Heart, Lung, and Blood Institute. Circulation 2010;122:1130-1133.
  3. Cikes M, Sutherland GR, Anderson LJ, Bijnens BH. The role of echocardiographic deformation imaging in hypertrophic myopathies. Nat Rev Cardiol 2010;7:384-396.
  4. Morita H, Seidman J, Seidman CE. Genetic causes of human heart failure. J Clin Invest 2005;115:518-526.
  5. Van der Ploeg AT, Reuser AJJ. Pompe’s disease. Lancet 2008;372:1342-1353.
  6. Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005;352:362–372.
  7. Maron BJ, Roberts WC, Arad M, et al. Clinical outcome and phenotypic expression in LAMP2 cardiomyophaty. JAMA 2009;301:1253-1259.
  8. Carbone I, Francone M, Chimenti C, et al. Right ventricular late enhancement as a magnetic resonance marker of glycogen storage disease. Circulation 2010;122:189-190.
  9. Zarate YA, Hopkin RJ. Fabry’s disease. Lancet 2008;372:1427-1435.
  10. Moon JCC, Sachdev B, Elkington AG, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease: evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003;24: 2151–2155.
  11. De Cobelli F, Esposito A, Belloni E, et al. Delayed-enhanced cardiac MRI for differentiation of Fabry’s disease from symmetric hypertrophic cardiomyopathy. AJR 2009;192:W97-W102.
  12. Fernández-Vizarra E, Bayona-Bafaluy MP, Enríquez JA. Cardiopathies of mitochondrial origin. Nat Rev Cardiol (CNIC Edition) 2010;7: 47-53.
  13. Conceição Silva M, Alves Meira ZM, Gurgel Giannetti J, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy. J Am Coll Cardiol 2007;49;1874-1879.
  14. Yilmaz A, Gdynia H-J, Ludolph AC, et al. Cardiomyopathy in a Duchenne muscular dystrophy carrier and her diseased son. Similar pattern revealed by cardiovascular MRI. Circulation 2010;121:e237-e239.
  15. Aoki Y, Niihori T, Narumi Y, et al. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat 2008;29:992-1006.
  16. Lehmann LH, Schaeufele T, Buss SJ, et al. A patient with Leopard syndrome and PTPN11 Mutation. Circulation 2009;119:1318-1329.
  17. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005;112: 2047-2060.
  18. Syed IS, Glockner JF, Feng D, et al. Role of Cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. J Am Coll Cardiol Img 2010;3:155-164.
  19. Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010;7:398-408.

Dres. Maja Cikes, George R. Sutherland, Lisa J. Anderson y Bart H. Bijnens

Nat Rev Cardiol. 2010;7:384-396

Dres. Andrew P. Landstrom and Michael J. Ackerman

Circulation 2010;122:2441-2450.

PRESENTACIÓN

En este “blog” o bitácora encontrarás temas relacionados con la especialidad de Cardiología. Está dirigido a todos los médicos implicados en el diagnóstico o tratamiento de los pacientes con enfermedades cardíacas y pretende destacar las noticias más interesantes relacionadas con esta especialidad.

Dr. Joan Llevadot
Todo el contenido de este blog esta bajo licencia de Creative Commons
Freicurv theme por flisterz y traducido por Trazos Web